Tactile Systems

Tactile Systems Technology, Inc. is a medical technology company. It develops and provides innovative medical devices for the treatment of chronic diseases at home. The firm focus on advancing the standard of care in treating chronic diseases in the home setting to improve patient outcomes and quality of life and help control rising healthcare expenditures. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Tactile Systems reports strong Q4 earnings, eyes growth and innovation

Tactile Systems delivered impressive Q4 2022 results with strong revenue growth, positive net income, and operational advancements, positioning the company for future success.
Strategic priorities for 2023 focus on sales team productivity, new product innovation, and operational efficiency, highlighting a commitment to sustained growth and market leadership.
Challenges include managing sales force turnover, supply chain constraints, and financial complexities post-2023, requiring proactive solutions and strategic decision-making.
Opportunities lie in capitalizing on revenue growth momentum, new product developments, and achieving an expanded adjusted EBITDA profile, signaling potential for continued success and value creation.

Tactile Systems reports robust Q1 growth, focuses on innovation

Tactile Systems delivered strong financial performance and operational advancements in Q1 2023, showcasing growth potential and a commitment to innovation and patient care.
While facing challenges in supply chain readiness and operational efficiency, the company's strategic focus on enhancing Medicare processes and product development presents opportunities for future success.
Overall, Tactile Systems' earnings call highlighted a positive trajectory with increased revenue guidance, product innovation, and a dedication to improving patient outcomes and support.

Tactile Systems (TCMD) reports strong Q2 earnings and growth outlook

Tactile Systems (TCMD) showcased robust financial performance, operational efficiency gains, and strategic talent additions in Q2 2023.
While facing challenges like AffloVest sales slowdown, the company raised revenue guidance and expects strong profitability with adjusted EBITDA of $25-27 million for 2023.
Opportunities lie in the head and neck trial's potential impact on revenue, Kylee app engagement benefits, and strategic priorities driving growth.

Tactile Systems reports revenue growth and strategic initiatives progress

Tactile Systems' Q3 performance showed revenue growth and improved profitability, supported by strategic initiatives and margin improvement efforts.
While facing challenges in AffloVest sales and patient acquisition, the company is optimistic about opportunities in therapy expansion and operational enhancements.
Consistent price increases and focus on technology-driven efficiencies are key strengths, with a focus on achieving ambitious 2025 targets.
Overall, Tactile Systems is navigating challenges while capitalizing on opportunities for growth and operational optimization.

Tactile Systems posts robust Q4 results, eyes growth opportunities

Tactile Systems delivered strong financial performance in Q4 2023, with revenue and net income growth. The company provided optimistic revenue guidance for 2024 and outlined strategic priorities for driving growth and enhancing customer experience. Challenges include anticipated headwinds and limited margin gains in the short term.

Tactile Systems reports Q1 growth, doubles EBITDA, eyes tech expansion

Tactile Systems reported solid financial performance with revenue growth and doubled adjusted EBITDA.
The company is strategically investing in tech advancements, new products, and expanding sales channels.
Challenges include addressing declining airway clearance revenues and optimizing sales rep impact.
Opportunities lie in expanding clinical trials, enhancing product user experience, and leveraging tech investments.

Tactile Systems (TCMD) reports robust Q2 earnings amidst Medicare challenges

Tactile Systems' Q2 2024 performance reflects solid financial growth and strategic initiatives. While facing challenges from Medicare documentation requirements, the company is focused on adapting to regulatory changes. Opportunities lie in capital allocation strategies, technology advancements, and market expansion efforts.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

San Francisco, California--(Newsfile Corp. - June 24, 2020) -  Hagens Berman urges investors in Tactile Systems Technology, Inc. (NASDAQ: TCMD) to submit their losses now.  The firm is investigating possible securities fraud and certain investors may have valuable claims.  Relevant Holding Period: Before June 8, 2020Visit: www.hbsslaw.com/investor-fraud/TCMDContact An Attorney Now: TCMD@hbsslaw.com844-916-0895Tactile Systems Technology (TCMD) Investigation: The investigation focuses on whether Tactile misrepresented the size of its market and

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS,  Encourages Tactile Systems Technology (TCMD) Investors to Contact its Attorneys: Firm Investigating  Possible Securities Fraud

San Francisco, California--(Newsfile Corp. - June 23, 2020) -  Hagens Berman urges investors in Tactile Systems Technology, Inc. (NASDAQ: TCMD) to submit their losses now.  The firm is investigating possible securities fraud and certain investors may have valuable claims. Relevant Holding Period: Before June 8, 2020Visit: www.hbsslaw.com/investor-fraud/TCMDContact An Attorney Now: TCMD@hbsslaw.com844-916-0895Tactile Systems Technology (TCMD) Investigation: The investigation focuses on whether Tactile misrepresented the size of its market

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS,  - Encourages Tactile Systems Technology (TCMD) Investors to Contact its Attorneys: Firm Investigating Possible Securities Fraud

LOS ANGELES--(BUSINESS WIRE)---- $TCMD #classaction--The Law Offices of Frank R. Cruz continues its investigation on behalf of Tactile Systems Technology, Inc. ("Tactile" or the "Company") (NASDAQ: TCMD) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On June 8, 2020, the investment analyst OSS Research issued a report on Tactile Medical entitled “Strong Sell On Tactile Systems (TCMD): Bloated S

The Law Offices of Frank R. Cruz Continues Its Investigation on Behalf of Tactile Systems Technology, Inc.

NEW YORK, June 10, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tactile Systems Technology, Inc. ("Tactile" or "the Company") (NASDAQ: TCMD). Investors who purchased Tactile securities are...

TCMD Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Tactile Systems Technology, Inc. and Encourages Investors to Contact the Firm

SAN FRANCISCO, June 9, 2020 /PRNewswire/ -- Hagens Berman urges investors in Tactile Systems Technology, Inc. (NASDAQ: TCMD) to submit their losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims. Relevant Holding Period: Before June...

HAGENS BERMAN,  NATIONAL TRIAL ATTORNEYS, Encourages Tactile Systems Technology (TCMD) Investors to Contact its Attorneys: Firm Investigating Possible Securities Fraud

SAN DIEGO, June 9, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Tactile Systems Technology, Inc. ("Tactile" or the "Company") (NASDAQ: TCMD). On June 8, 2020, OSS Research issued a report...

(TCMD) Alert: Johnson Fistel Investigates Tactile Systems Technology; Investors Suffering Losses Encouraged to Contact Firm

MINNEAPOLIS, May  21, 2020  (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today announced that Daniel L. Reuvers has been appointed President and Chief Executive Officer, effective June 8, 2020, to succeed Gerald R. Mattys who is retiring, as previously disclosed. Mr. Reuvers will also join the Board of Directors, effective June 8, 2020, filling a seat created by Mr. Mattys’ retirement from the Board, effective that same day. Mr. Mattys will serve as a consultant to the Company until June 2021 to ensure a seamless transition.

Tactile Systems Technology, Inc. Announces Appointment of Daniel L.

Tactile Systems Technology, Inc. (TCMD) CEO Gerald Mattys on Q1 2020 Results - Earnings Call Transcript

First Quarter Revenue Increased 16% Year-Over-Year; 26% Year-Over-Year on an Operational Basis First Quarter Revenue Increased 16% Year-Over-Year; 26% Year-Over-Year on an Operational Basis

Tactile Systems Technology, Inc. Reports First Quarter 2020 Financial Results

Preliminary First Quarter Revenue Increased 14% to 17% Year-Over-Year; 24% to 27% Year-Over-Year on an Operational Basis Preliminary First Quarter Revenue Increased 14% to 17% Year-Over-Year; 24% to 27% Year-Over-Year on an Operational Basis

Tactile Systems Technology, Inc. Reports Preliminary First Quarter 2020 Revenue Results, Withdraws Full Year 2020 Financial Outlook and Provides COVID-19 Business Update

Tactile Systems Technology, Inc. (TCMD) CEO Gerald Mattys on Q4 2019 Results - Earnings Call Transcript

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of -4.35% and 1.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Q4 Earnings Miss Estimates

MINNEAPOLIS, Feb.  24, 2020  (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, announced today that the Company’s motion to dismiss the qui tam complaint filed against the Company has been denied by the court.

Tactile Medical Announces Update to Qui Tam Complaint

Tactile Systems Technology (TCMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tactile Systems Technology (TCMD) Reports Next Week: Wall Street Expects Earnings Growth

Researchers concluded that Chronic Venous Insufficiency, not cancer-related therapy, may be the most common cause of Lower Extremity Lymphedema in the United States, with an estimated prevalence of 16 million individuals Researchers concluded that Chronic Venous Insufficiency, not cancer-related therapy, may be the most common cause of Lower Extremity Lymphedema in the United States, with an estimated prevalence of 16 million individuals

Tactile Medical Announces New Clinical Publication Highlighting the Role of Chronic Venous Insufficiency in Causing Lower Extremity Lymphedema

Tactile Systems Technology has been struggling lately, but the selling pressure may be coming to an end soon.

Tactile Systems Technology Sees Hammer Chart Pattern: Time to Buy?

2019 Revenue Increased 31% Year-Over-Year; Fourth Quarter Revenue Increased 21% to 22% Year-Over-Year 2019 Revenue Increased 31% Year-Over-Year; Fourth Quarter Revenue Increased 21% to 22% Year-Over-Year

Tactile Systems Technology, Inc. Reports Preliminary Full Year and Fourth Quarter 2019 Revenue Results; Introduces Full Year 2020 Financial Outlook; Announces CEO Intends to Retire in 2020

T-Mobile US

TriNet Group

Do you want to pick stocks that carry a high potential to continue to drive their share prices higher?

A Trio of Fast Growing EPS Stocks

Tactile Systems Technology, Inc. (TCMD) CEO Jerry Mattys on Q3 2019 Results - Earnings Call Transcript

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 0.00% and 9.53%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Q3 Earnings Match Estimates

Integra LifeSciences Holdings

IART vs. TCMD: Which Stock Is the Better Value Option?

MINNEAPOLIS, Aug.  27, 2019  (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the following upcoming investor conferences:

Tactile Medical to Present at Two Upcoming Investor Conferences in September and October

Tactile Systems Technology, Inc. (TCMD) CEO Jerry Mattys on Q2 2019 Results - Earnings Call Transcript

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 180.00% and 6.96%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Q2 Earnings and Revenues Top Estimates

Hologic

HOLX vs. TCMD: Which Stock Is the Better Value Option?

News for Tactile Systems Stock (TCMD)